Endometrial carcinoma cells are nonpermissive for CD44-erbB2 interactions

Manja Wobus; Robin Kuns; Irene Sheyn; Bruce A. Werness; Nader Husseinzadeh; Bernard S. Aron; Larry S. Sherman

doi:10.1097/00022744-200209000-00010

Endometrial carcinoma cells are nonpermissive for CD44-erbB2 interactions

Manja Wobus, Robin Kuns, Irene Sheyn, Bruce A. Werness, Nader Husseinzadeh, Bernard S. Aron, Larry S. Sherman

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The erbB2 receptor tyrosine kinase and the CD44 transmembrane glycoprotein interact with one another in numerous cell types. This interaction helps to maintain erbB2 activity that contributes to tumor progression. We investigated whether CD44 and erbB2 similarly interact in endometrial carcinomas in vitro and in situ. In contrast to other carcinomas, CD44 did not colocalize with erbB2 in any of the 51 cases of endometrial cancer analyzed. CD44 also did not coimmunoprecipitate or colocalize with erbB2 in two endometrial carcinoma cell lines. We propose that the lack of CD44-erbB2 interactions may reduce the contribution of erbB2 to endometrial carcinoma progression.

Original language	English (US)
Pages (from-to)	242-246
Number of pages	5
Journal	Applied Immunohistochemistry and Molecular Morphology
Volume	10
Issue number	3
DOIs	https://doi.org/10.1097/00022744-200209000-00010
State	Published - Sep 2002
Externally published	Yes

Keywords

CD44
Endometrial carcinoma
erbB2

ASJC Scopus subject areas

Pathology and Forensic Medicine
Histology
Medical Laboratory Technology

Access to Document

10.1097/00022744-200209000-00010

Cite this

@article{0c5900f6da244a2cb73a46740094e8da,

title = "Endometrial carcinoma cells are nonpermissive for CD44-erbB2 interactions",

abstract = "The erbB2 receptor tyrosine kinase and the CD44 transmembrane glycoprotein interact with one another in numerous cell types. This interaction helps to maintain erbB2 activity that contributes to tumor progression. We investigated whether CD44 and erbB2 similarly interact in endometrial carcinomas in vitro and in situ. In contrast to other carcinomas, CD44 did not colocalize with erbB2 in any of the 51 cases of endometrial cancer analyzed. CD44 also did not coimmunoprecipitate or colocalize with erbB2 in two endometrial carcinoma cell lines. We propose that the lack of CD44-erbB2 interactions may reduce the contribution of erbB2 to endometrial carcinoma progression.",

keywords = "CD44, Endometrial carcinoma, erbB2",

author = "Manja Wobus and Robin Kuns and Irene Sheyn and Werness, {Bruce A.} and Nader Husseinzadeh and Aron, {Bernard S.} and Sherman, {Larry S.}",

year = "2002",

month = sep,

doi = "10.1097/00022744-200209000-00010",

language = "English (US)",

volume = "10",

pages = "242--246",

journal = "Applied Immunohistochemistry and Molecular Morphology",

issn = "1062-3345",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Endometrial carcinoma cells are nonpermissive for CD44-erbB2 interactions

AU - Wobus, Manja

AU - Kuns, Robin

AU - Sheyn, Irene

AU - Werness, Bruce A.

AU - Husseinzadeh, Nader

AU - Aron, Bernard S.

AU - Sherman, Larry S.

PY - 2002/9

Y1 - 2002/9

N2 - The erbB2 receptor tyrosine kinase and the CD44 transmembrane glycoprotein interact with one another in numerous cell types. This interaction helps to maintain erbB2 activity that contributes to tumor progression. We investigated whether CD44 and erbB2 similarly interact in endometrial carcinomas in vitro and in situ. In contrast to other carcinomas, CD44 did not colocalize with erbB2 in any of the 51 cases of endometrial cancer analyzed. CD44 also did not coimmunoprecipitate or colocalize with erbB2 in two endometrial carcinoma cell lines. We propose that the lack of CD44-erbB2 interactions may reduce the contribution of erbB2 to endometrial carcinoma progression.

AB - The erbB2 receptor tyrosine kinase and the CD44 transmembrane glycoprotein interact with one another in numerous cell types. This interaction helps to maintain erbB2 activity that contributes to tumor progression. We investigated whether CD44 and erbB2 similarly interact in endometrial carcinomas in vitro and in situ. In contrast to other carcinomas, CD44 did not colocalize with erbB2 in any of the 51 cases of endometrial cancer analyzed. CD44 also did not coimmunoprecipitate or colocalize with erbB2 in two endometrial carcinoma cell lines. We propose that the lack of CD44-erbB2 interactions may reduce the contribution of erbB2 to endometrial carcinoma progression.

KW - CD44

KW - Endometrial carcinoma

KW - erbB2

UR - http://www.scopus.com/inward/record.url?scp=0036735275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036735275&partnerID=8YFLogxK

U2 - 10.1097/00022744-200209000-00010

DO - 10.1097/00022744-200209000-00010

M3 - Article

C2 - 12373151

AN - SCOPUS:0036735275

SN - 1062-3345

VL - 10

SP - 242

EP - 246

JO - Applied Immunohistochemistry and Molecular Morphology

JF - Applied Immunohistochemistry and Molecular Morphology

IS - 3

ER -

Endometrial carcinoma cells are nonpermissive for CD44-erbB2 interactions

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this